Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Relugolix

Review the clinical trials studying relugolix on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Status: Active
Location: 553 locations
Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Based on PET Imaging, INDICATE Trial
Status: Active
Location: 305 locations
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Status: Active
Location: 215 locations
Relugolix or Leuprolide for Treatment in Men with Prostate Cancer
Status: Active
Location: 7 locations
Standard of Care Treatment (Hormonal Therapy and Stereotactic Ablative Radiation Therapy) Alone or in Combination with Niraparib, Abiraterone and Prednisone for the Treatment of Metastatic Prostate Cancer, KNIGHTS Trial
Status: Active
Location: 7 locations
2141-V11 in Combination with Standard Therapy for the Treatment of Prostate Cancer Prior to Surgery
Status: Active
Location: 7 locations
Relugolix and Enzalutamide in Combination with Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Status: Active
Location: 6 locations
SBRT and Relugolix for the Treatment of Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer, SUGAR Trial
Status: Active
Location: 5 locations
MRI-Guided LEAD Stereotactic Radiotherapy with or without Ultra-Short Term Androgen Deprivation Therapy for the Treatment of Prostate Cancer, the Miami UAdapt Trial
Status: Active
Location: 4 locations
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for the Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Status: Active
Location: 3 locations
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Status: Active
Location: 2 locations
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Status: Active
Location: 2 locations
A Study of Personalized Apalutamide Treatment for Improving Quality of Life in Patients with Prostate Cancer after Post Operative Radiation, PROSTATE-IQ Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Leuprolide and Abiraterone Acetate (AA) versus Relugolix and AA for the Treatment of Non-Metastatic Recurrent Prostate Cancer, the REVELUTION-2 Trial
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Relugolix in Combination with Radiation Therapy for Treating Patients with High Risk Prostate Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Relugolix or Leuprolide for the Treatment of Cardiac Function in Patients with Prostate Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
MR-Linac-Guided Stereotactic Body Radiation Therapy with Androgen Deprivation Therapy for the Treatment of Locally Recurrent Prostate Adenocarcinoma
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Adaptive Androgen Deprivation Therapy and Docetaxel for the Treatment of Metastatic Castration Sensitive Prostate Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Metastasis-Directed Radiotherapy for the Treatment of Men with Oligometastatic Prostate Cancer, METANOVA Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Androgen Deprivation Therapy and SBRT versus SBRT Alone for the Treatment of Unfavorable Intermediate Risk Prostate Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York